Reset Pharma

Reset Pharma is a clinical-stage biotechnology company pioneering the development of psychedelic-based therapies for patients facing life-threatening illnesses. The company's primary focus is addressing the psychological burden of disease, specifically targeting demoralization and existential distress in cancer patients. Its lead candidate, RPC-101 (psilocybin), is being evaluated in Phase 2 clinical trials as a treatment combined with structured psychotherapy. By leveraging the neuroplastic effects of psilocybin, Reset Pharma seeks to provide long-lasting mental health benefits through a limited number of dosing sessions. The leadership team comprises veterans from the pharmaceutical industry with expertise in drug development and commercialization.